Baxter reports positive data from von Willebrand disease drug trial

Baxter has announced new data from a phase III clinical trial evaluating a promising treatment for von Willebrand disease, the most common type of inherited bleeding disorder.

Additional data from the phase III clinical trial of BAX 111, the first highly-purified recombinant von Willebrand factor, has shown that the compound met its primary efficacy endpoint, as defined by the number of patients who achieved treatment success for control of bleeding episodes.

All patients treated in the full analysis set experienced a 100 percent treatment success rating based on a four-point efficacy scale, comparing the estimated number of infusions needed to treat the bleeding episodes to the actual number administered.

Moreover, efficacy for all treated bleeds was rated excellent or good, while the majority of events were resolved with a single infusion.

John Orloff, vice-president and global head of research and development at Baxter BioScience, said: "With an expanding pipeline across multiple bleeding disorders, our goal is to advance programmes that can effectively manage these challenging disorders and help improve patient lives."

Baxter offered further evidence of its support for bleeding disorder patients last week by taking part in World Haemophilia Day, an event dedicated to raising awareness of the condition globally.